Orchestra BioMed Holdings, Inc.
NASDAQ:OBIOBiotechnology
+$0.05 today
- Market cap
- $587.14M
- Beta
- 0.50
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.42
Volume 1.20M
Average 0.22M
OBIO Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Orchestra BioMed Holdings, Inc.NASDAQ: OBIO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $90K rose 8.4% year over year, ahead of the +5.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 9.8% from the prior quarter. Over 3 fiscal years it compounded at +13.8% a year.
Context
- Depreciation & amortization amounted to 1.0% of revenue in FY2025, down 10.7 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +8.4% holds above the trailing-twelve-month pace of +5.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 327K USD
- Year-over-year change
- +6.2%
- 4-year CAGR
- +15.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 327K | +6.2% |
| FY2024 | 2024-12-31 | 308K | +7.3% |
| FY2023 | 2023-12-31 | 287K | +29.3% |
| FY2022 | 2022-12-31 | 222K | +22.7% |
| FY2021 | 2021-12-31 | 181K | — |
Depreciation & Amortization vs competitors
How OBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +5.4% is the 5th highest of 11, against a peer median of -11.2%.
- Depreciation & amortization amounts to 1.0% of revenue for OBIO, versus a peer median of 29.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.54M USD | -16.0% | -1.1% | 3350.2% | |
| LTM Mar 2026 | $4.93M USD | +55.9% | +19.6% | 7.1% | |
| LTM Mar 2026 | $4.42M USD | +82.7% | +85.3% | 31.9% | |
| LTM Mar 2026 | $3.13M USD | -28.6% | +0.0% | 27.9% | |
| FY2025 | €2.8M EUR | -46.2% | +47.6% | 62.4% | |
| LTM Mar 2026 | $1.88M USD | -43.4% | +65.8% | 3.4% | |
| LTM Mar 2026 | $1.67M USD | -6.4% | +8.9% | 10.0% | |
| LTM Mar 2026 | $369K USD | +11.1% | +13.4% | — | |
| LTM Mar 2026 | $334K USD | +5.4% | +13.8% | 1.0% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $262.3K USD | +45.1% | +30.9% | — |
| LTM Mar 2026 | $226K USD | -16.3% | +27.5% | 383.1% | |
| Peer median (excluding OBIO) | — | -11.2% | +23.6% | 29.9% | |
Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | (782K) | 3.53M | 2.76M | 2.64M | 33.48M |
| Cost of Revenue | 199K | 322K | 186K | 204K | 190K |
| Gross Profit | (981K) | 3.21M | 2.57M | 2.43M | 33.29M |
| Gross Margin | 125.4% | 90.9% | 93.3% | 92.3% | 99.4% |
| Research & Development | 12.89M | 21.95M | 33.82M | 42.8M | 58.19M |
| Selling, General & Admin | 7.93M | 13.92M | 20.26M | 23.93M | 26.91M |
| Operating Expenses | 20.82M | 35.87M | 54.08M | 66.74M | 85.1M |
| Depreciation & Amortization | 181K | 222K | 287K | 308K | 327K |
| EBITDA | (21.91M) | (33.39M) | (48.83M) | (60.72M) | (51.23M) |
| EBITDA Margin | 2801.3% | -945.0% | -1769.3% | -2301.6% | -153.0% |
| Operating Income | (21.8M) | (32.66M) | (51.51M) | (64.3M) | (51.81M) |
| Operating Margin | 2787.6% | -924.3% | -1866.2% | -2437.5% | -154.7% |
| Interest Income | 0 | 50K | 3.85M | 3.36M | 0 |
| Interest Expense | 927K | 0 | 0 | 0 | 1.15M |
| Other Income / Expenses | (1.22M) | (951K) | 2.39M | 3.28M | (894K) |
| Income Before Tax | (23.01M) | (33.61M) | (49.12M) | (61.02M) | (52.7M) |
| Pre-Tax Margin | 2943.0% | -951.3% | -1779.7% | -2313.3% | -157.4% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.01M) | (33.61M) | (49.12M) | (61.02M) | (52.7M) |
| Net Margin | 2943.0% | -951.3% | -1779.7% | -2313.3% | -157.4% |
| EPS (Basic) | (0.02) | (1.32) | (1.48) | (1.66) | (1.38) |
| EPS (Diluted) | (0.02) | (1.32) | (1.48) | (1.66) | (1.38) |
| Weighted Avg Shares | 20.45M | 25.47M | 33.23M | 36.82M | 38.39M |
| Weighted Avg Shares (Diluted) | 20.45M | 25.47M | 33.23M | 36.82M | 38.39M |
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
Intrinsic Alpha fair value
Locked
Current Price
$7.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.